US2007178551A1PendingUtilityA1

Methods for producing modified glycoproteins

62
Assignee: GLYCOFI INCPriority: Jun 28, 2000Filed: Nov 1, 2005Published: Aug 2, 2007
Est. expiryJun 28, 2020(expired)· nominal 20-yr term from priority
A61P 3/10A61P 37/00C12N 9/1048C12P 21/005C12N 1/14C12N 15/80C12Y 302/01C12N 9/2488C07K 2319/05C12N 15/79C12Y 302/01113C07K 2319/04C12N 15/81A61P 29/00C12P 21/02
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man 5 GlcNAc 2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.

Claims

exact text as granted — not AI-modified
1 - 8 . (canceled)  
     
     
         9 . A method for producing a recombinant glycoprotein comprising an N-glycan structure that comprises a GlcNAcMan 5 GlcNAc 2  glycoform in a lower eukaryotic host cell selected or genetically modified to produce N-glycan structures having an excess of 30 mole % of a Man 5 GlcNAc 2  glycoform that can serve as a substrate for GlcNAc transferase I in vivo, the method comprising the step of introducing into said host cell a nucleic acid encoding a GlcNAc transferase I enzyme selected to have optimal activity in the ER or Golgi of said host cell, the enzyme comprising: 
 (a) a GlcNAc transferase I catalytic domain having optimal activity in said ER or Golgi at a pH between 5.1 and 8.0; fused to    (b) a cellular targeting signal peptide not normally associated with the catalytic domain selected to target the GlcNAc transferase I enzyme to the ER or Golgi apparatus of the host cell;    whereby, upon passage of the recombinant glycoprotein through the ER or Golgi apparatus of the host cell, a recombinant glycoprotein comprising a GlcNAcMan 5 GlcNAc 2  glycoform is produced.    
     
     
         10 . A method for producing a recombinant glycoprotein comprising an N-glycan comprising a GlcNAcMan 3 GlcNAc 2  glycoform in a lower eukaryotic host cell selected or genetically modified to produce N-glycan structures having an excess of 30 mole % of a Man 5 GlcNAc 2  glycoform that are converted in vivo to a GlcNAcMan 5 GlcNAc 2  glycoform by GlcNAc transferase I activity localized in the ER or Golgi apparatus of the host cell, the method comprising the step of introducing into the host cell a nucleic acid encoding a mannosidase II enzyme selected to have optimal activity in the ER or Golgi of said host cell, the enzyme comprising: 
 (a) a mannosidase II catalytic domain having optimal activity in said ER or Golgi at a pH between 5.1 and 8.0; fused to    (b) a cellular targeting signal peptide not normally associated with the catalytic domain selected to target the mannosidase II enzyme to the ER or Golgi apparatus of the host cell;    whereby, upon passage of the recombinant glycoprotein through the ER or Golgi apparatus of the host cell, a recombinant glycoprotein comprising a GlcNAcMan 3 GlcNAc 2  glycoform is produced.    
     
     
         11 . A method for producing a recombinant glycoprotein comprising an N-glycan comprising a GlcNAc 2 Man 3 GlcNAc 2  glycoform in a lower eukaryotic host cell selected or genetically modified to produce N-glycan structures having an excess of 30 mole % of a Man 5 GlcNAc 2  glycoform that are converted in vivo to a GlcNAcMan 3 GlcNAc 2  glycoform by GlcNAc transferase I and mannosidase II localized in the ER or Golgi apparatus of the host cell, the method comprising the step of introducing into the host cell a nucleic acid encoding a GlcNAc transferase II enzyme selected to have optimal activity in the ER or Golgi of said host cell, the enzyme comprising: 
 (a) a GlcNAc transferase II catalytic domain having optimal activity in said ER or Golgi at a pH between 5.1 and 8.0; fused to    (b) a cellular targeting signal peptide not normally associated with the catalytic domain selected to target the GlcNAc transferase II enzyme to the ER or Golgi apparatus of the host cell;    whereby, upon passage of the recombinant glycoprotein through the ER or Golgi apparatus of the host cell, a recombinant glycoprotein comprising a GlcNAc 2 Man 3 GlcNAc 2  glycoform is produced.    
     
     
         12 . The method of  claim 9 ,  10  or  11 , further comprising the step of introducing into the host cell one or more additional nucleic acids encoding one or more additional enzymes or catalytically active domains thereof selected from the group consisting of glycosyltransferases and glycosidases.  
     
     
         13 . The method of  claim 12 , wherein said additional enzyme or catalytic domain thereof is an alpha-1,2 mannosidase.  
     
     
         14 . The method of  claim 9 ,  10  or  11 , wherein the recombinant glycoprotein comprising the N-glycan is further modified to comprise one or more sugars selected from the group consisting of N-acetylglucosamine, galactose, sialic acid and fucose.  
     
     
         15 . The method of  claim 12 , wherein at least one of said one or more enzymes or catalytically active domains thereof is localized in the host by forming a fusion protein between a catalytic domain of the enzyme and a cellular targeting signal peptide.  
     
     
         16 . The method of  claim 15 , wherein the fusion protein is encoded by at least one genetic construct formed by the in-frame ligation of a DNA fragment encoding a cellular targeting signal peptide with a DNA fragment encoding a glycosylation enzyme or catalytically active fragment thereof.  
     
     
         17 . The method of  claim 15 , wherein the catalytic domain encodes: a glycosidase; a glycosyltransferase selected from the group consisting of GnT I, GnT II, GnT III, GnT IV, GnT V, GnT VI, GalT, Fucosyltransferase and ST; a transporter selected from the group consisting of UDP-GlcNAc transporter, UDP-galactose transporter, GDP-fucose transporter, CMP-sialic acid transporter; or a nucleotide diphosphatase, and wherein the catalytic domain has optimal activity at a pH between 5.1 and 8.0.  
     
     
         18 . The method of  claim 9 ,  10  or  11 , further comprising the step of introducing into the host cell one or more additional nucleic acids encoding one or more additional enzymes selected from the group consisting of UDP-GlcNAc, UDP-Gal, CMP-NANA and GDP-Fuc.  
     
     
         19 . The method of  claim 9 ,  10  or  11 , wherein the host is genetically modified to express a UDP- or GDP-specific diphosphatase.  
     
     
         20 . The method of  claim 9 ,  10  or  11 , wherein the host is genetically modified to express GnTI and a UDP-GlcNAc transporter.  
     
     
         21 . The method of any one of claims  9 ,  10  or  11 , wherein the host is selected from the group consisting  Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia  sp.,  Saccharomyces cerevisiae, Saccharomyces  sp.,  Hansenula polymorpha, Kluyveromyces  sp.,  Candida albicans, Aspergillus nidulans , and  Trichoderma reesei.    
     
     
         22 . The method of  claim 9 ,  10  or  11 , wherein the host further lacks the activity of one or more enzymes selected from the group consisting of mannosyltransferases and phosphomannosyltransferases.  
     
     
         23 . The method of  claim 22 , wherein the host lacks an enzyme activity with respect to the N-glycan on a glycoprotein, the activity selected from the group consisting of 1,6 mannosyltransferase; 1,3 mannosyltransferase; and 1,2 mannosyltransferase.  
     
     
         24 . The method of  claim 9 ,  10  or  11 , further comprising the step of isolating the recombinant glycoprotein subsequent to passage of the recombinant glycoprotein through the ER or Golgi apparatus of the host cell.  
     
     
         35 . The method of  claim 24 , further comprising the step of subjecting the isolated glycoprotein to at least one further glycosylation reaction in vitro, subsequent to its isolation from the host.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.